MyFinsight
Home
Blog
About
Contact
Download
Download image
Revenues
$2,320,126K
(6.98%↑ Y/Y)
Interest income
$69,213K
(-10.29%↓ Y/Y)
Net income
$782,570K
(50.13%↑ Y/Y)
Deferred taxes
-$126,237K
(-312.31%↓ Y/Y)
Proceeds from maturities
and sales of...
$1,022,866K
(16.59%↑ Y/Y)
Canceled cashflow
$1,606,769K
Stock-based compensation
$112,983K
(20.40%↑ Y/Y)
Depreciation and
amortization
$29,055K
(0.87%↑ Y/Y)
Non-cash lease expense
$24,229K
(-11.77%↓ Y/Y)
Inventory
-$12,225K
(-124.19%↓ Y/Y)
Acquired in-process
research and development...
$11,999K
(-76.36%↓ Y/Y)
Accrued collaboration
liabilities
$1,899K
(1374.50%↑ Y/Y)
Net cash provided by
operating activities
$884,267K
(26.33%↑ Y/Y)
Net cash provided by
(used in) investing...
$350,441K
(400.08%↑ Y/Y)
Canceled cashflow
$216,930K
Canceled cashflow
$672,425K
Development
$567,843K
(-14.72%↓ Y/Y)
Selling, general and
administrative
$446,536K
(4.10%↑ Y/Y)
Other segment items
$260,126K
(-12.81%↓ Y/Y)
Provision for income taxes
$158,636K
(-1.08%↓ Y/Y)
Drug discovery
$89,931K
(-5.18%↓ Y/Y)
Cost of goods sold
$83,697K
(9.82%↑ Y/Y)
Net increase
(decrease) in cash and cash...
$265,114K
(681.14%↑ Y/Y)
Canceled cashflow
$969,594K
Prepaid expenses and
other assets
$133,771K
(530.42%↑ Y/Y)
Accounts payable and
other liabilities
-$50,152K
(-129.15%↓ Y/Y)
Trade receivables,
net
$21,398K
(-23.44%↓ Y/Y)
Other, net
$11,609K
(-14.80%↓ Y/Y)
Proceeds from issuance of
common stock under the...
$49,137K
(-20.55%↓ Y/Y)
Purchases of marketable
securities
$632,497K
(-31.84%↓ Y/Y)
Acquired in-process
research and development...
$31,499K
(-16.56%↓ Y/Y)
Purchases of property,
equipment and other, net
$8,429K
(-70.36%↓ Y/Y)
Net cash used in
financing activities
-$969,594K
(-54.20%↓ Y/Y)
Canceled cashflow
$49,137K
Payments for repurchases
of common stock
$947,511K
(45.32%↑ Y/Y)
Taxes paid related to
net share...
$71,220K
(84.39%↑ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)